Safety of a specific COX-2 inhibitor in aspirin-induced asthma.

@article{Szczeklik2001SafetyOA,
  title={Safety of a specific COX-2 inhibitor in aspirin-induced asthma.},
  author={Andrzej Szczeklik and Ewa Nizankowska and Grazyna Bochenek and Krzysztof Nagraba and Filip Mejza and Monika Swierczyńska},
  journal={Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},
  year={2001},
  volume={31 2},
  pages={219-25}
}
In a subset of patients with asthma, aspirin and several other non-steroidal anti-inflammatory drugs (NSAID) that inhibit simultaneously cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) precipitate dangerous asthmatic attacks. We tested the hypothesis that in patients with aspirin-induced asthma the attacks are triggered by inhibition of COX-1 and not COX-2. In twelve asthmatic patients (seven men, five women, average age 39 years) oral aspirin challenge precipitated symptoms of bronchial… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Late reaction to oral nystatin: the importance of patch testing.

Journal of investigational allergology & clinical immunology • 2009
View 5 Excerpts
Highly Influenced

Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease.

Journal of investigational allergology & clinical immunology • 2013
View 4 Excerpts
Highly Influenced

The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity.

Journal of investigational allergology & clinical immunology • 2004
View 11 Excerpts
Highly Influenced

Samter’s Triad: State of the Art

Clinical and experimental otorhinolaryngology • 2018

Similar Papers

Loading similar papers…